Trial · NCT06682169
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169, Phase 3, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease. Trials, record NCT06682169. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06682169
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- NCT number
- NCT06682169
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 182 participants, estimated
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- Graft-versus-host Disease
- Interventions
- Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
- First posted
- 2024-11-12
- Last updated
- 2025-12-08
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective remission rate in the 24th week (ORR) | Week 24 | Researchers evaluated each organ according to the consensus criteria of the NIH 2014 conference, and at week 24, the percentage of subjects with complete response (CR) or partial response (PR) in all assessable organs was determined. |
| Secondary | Best Objective Response Rate (BOR) | Week 24 | The best therapeutic effect among all therapeutic outcomes |
| Secondary | Duration of Relief (DOR) | Through study completion, an average of 2 year | The duration of symptom relief for patients after receiving treatment |
| Secondary | Improvement in Lee cGVHD symptom score of subjects in week 24 | Week 24 | The Lee cGVHD Symptom Score is a tool used to assess the severity of symptoms in chronic graft-versus-host disease (cGVHD), ranging from 0 to 4 points, with a maximum total score of 16 points. The higher the score, the more severe the cGVHD symptoms. |
| Secondary | Failure free survival (FFS) | Weeks 2, 4, 8, 16, 36, 48, 60, 72, 84, 96 | The time from the start of treatment to the occurrence of disease progression or death for any reason in the patient |
| Secondary | Primary disease recurrence rate (MR) | Weeks 8, 16,24， 36, 48 | The probability of recurrence of the patient's disease within a certain period of time. |
| Secondary | Non-Relapse Mortality (NRM) | Weeks 8, 16,24， 36, 48 | NRM was defined as death without recurrent or progressive disease |
| Secondary | Overall survival (OS) | Through study completion, an average of 2 year | From randomization to the time of death caused by any reason |
| Secondary | Percentage of subjects whose daily glucocorticoid dose decreased | Week 24 | Percentage of subjects whose daily glucocorticoid dose decreased by ≥ 50% in week 24, and percentage of subjects who discontinued all glucocorticoids |
| Secondary | Changes in the Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT) | Through study completion, an average of 2 year | The FACT-BMT scale is a tool used to evaluate the quality of life (QOL) of patients after hematopoietic stem cell transplantation, the scale is filled out by the person closest to the patient, and each question has five possible answers on a scale of 0-4. Answer each question item based on the patient's actual situation in the past week, and mark the corresponding number with a "√" |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06682169
GET https://conductscience.org/api/trials/v1/NCT06682169/registered